| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1915508 | Journal of the Neurological Sciences | 2008 | 4 Pages |
Abstract
Inhibition of leukocyte trafficking using antibody blockade of the alpha4 (α4)-integrins has now been validated as a therapeutic approach for the treatment of multiple sclerosis (MS). This positive validation has led to the discovery of small molecule α4 antagonists that are progressing through clinical trials. The challenges in development of these antagonists will be discussed along with a clinical update on the most advanced candidates.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Richard J. Davenport, James R. Munday,